The latest
market report published by Credence Research, Inc. “Global Irritable Bowel
Syndrome with Diarrhea (IBS-D) Market - Growth, Share, Opportunities,
Competitive Analysis, and Forecast, 2016-2022,” the irritable bowel syndrome
with diarrhea (IBS-D) drugs market was valued at USD 289.3 Mn in 2015, and is
expected to reach USD 1,115.06 Mn by 2022, expanding at a CAGR of 13.89% from
2016 to 2022.
Browse the full report Irritable Bowel Syndrome with
Diarrhea (IBS-D) 2016–2022 report at http://www.credenceresearch.com/report/irritable-bowel-syndrome-ibs-with-Diarrhea-drugs-market
Market Insights
IBS affects
between 10% to 20% individuals in the developed countries. Since the underlying
cause of IBD remains unknown, the treatment market for the same is observed to
be unvisited and is characterized by very few indicated drugs. By far,
alosetron has been the only drug approved for IBS-D treatment. With the
approval for eluxadoline (Viberzi) and rifaximin (Xifaxan), new avenues in the
IBS-D treatment market have opened, giving hopes to the patients.
Both Viberzi
and Xifaxan are determined to be safe, Viberzi may receive controlled substance
label due to risk of potential abuse. Viberzi and other IBS-D drugs act on
opioid receptors, thus it is a mu receptor antagonist and kappa receptor
antagonist. On the other hand, Xifaxan is viewed as a curative regimen, since
it acts by altering the bacterial flora in the guts.
Xifaxan has
been reportedly prescribed off label for treating IBS-D. Its formal sanction
will thus support the growth in demand for the drug in the forecast period.
Xifaxan is prescribed for a 14 day, thrice a day dosage; with a further
additional 1 week dosage if the need arises. However, its long term role in
efficiently containing IBS-D is still questioned. Viberzi, on the other hand,
easily fits the profile of everyday medication for chronic disease treatment,
similar to diabetes and CVD treatments. Further safety and effective
assessments on these drugs are lined up, which will clear the market status of
the two drugs.
The market for
Viberzi is expected to cross USD 6 Mn mark by 2022, whereas Xifaxan market is
expected to progress at a CAGR of moderate 4.46% during 2016-2022. IBS-D
affects over 15 million Americans, with no single drugs having a clear domination
in the market. Loperamide, angidepressants, alosetron, bile acid binders and
similar such drugs were the standard treatments in the past. Medical
professionals have largely relied on trial and error approach for treating
IBS-D patients.
For More Reports Related to This Category @
http://www.credenceresearch.com/industry/pharmaceuticals-market
About Us:
Credence
Research is a worldwide market research and counseling firm that serves driving
organizations, governments, non legislative associations, and not-for-benefits.
We offer our customers some assistance with making enduring enhancements to
their execution and understand their most imperative objectives. Over almost a century,
we’ve manufactured a firm extraordinarily prepared to this task.
Media Contact
Name: Chris Smith (Global Sales
Manager)
Address:
105 N 1st ST #429, SAN JOSE, CA 95103 US
Ph: 1-800-361-8290
No comments:
Post a Comment